Expert Management of HBV Infection: Weighing Patient Factors in Treatment Decisions
  • CME

In this interactive virtual module, expert faculty discuss how they weigh various patient factors to aid in management decisions for patients with HBV infection; topics include treatment candidacy, individualizing treatment, patient monitoring, and approaches to immune-tolerant HBV infection.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Program Director
Steven L. Flamm, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: July 7, 2020 Expiration: July 6, 2021
Multimedia Expert Management of HBV Infection: Weighing Patient Factors in Treatment Decisions
This program is divided into short segments which you can review from the Activity landing page.
Module Overview (4 minutes)
Meet the expert faculty and listen to a brief overview of the global HBV burden and natural history.
Launch Module Overview (4 minutes)
Case 1: HBeAg-Negative Woman With Chronic HBV Infection (21 minutes)
In this case, faculty review the patient evaluations necessary to determine treatment candidacy, the goals of therapy, optimal patient monitoring, and the importance of HCC screening.
Launch Case 1: HBeAg-Negative Woman With Chronic HBV Infection (21 minutes)
Case 2: HBeAg-Positive Man With Chronic HBV Infection (26 minutes)
In this case, faculty review considerations for individualized treatment selection for patients with HBV infection.
Launch Case 2: HBeAg-Positive Man With Chronic HBV Infection (26 minutes)
Case 3: Woman With Immune-Tolerant HBV Infection (24 minutes)
Faculty discuss treatment candidacy considerations for patients with immune tolerant HBV infection, emphasizing current guidelines and recent data.
Launch Case 3: Woman With Immune-Tolerant HBV Infection (24 minutes)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Determine treatment candidacy for each individual patient with chronic HBV infection
  • Identify key factors that aid in determining the most appropriate monitoring strategy for patients not on treatment
  • Select an appropriate treatment regimen for diverse patients, based on available treatment options, and individualized application of clinical practice guidelines and current data

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Gilead Sciences

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Professor of Medicine
Department of Gastroenterology and Hepatology
Stanford University Medical Center
Palo Alto, California

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD, has disclosed that she has received consulting fees from Alnylam, Bristol-Myers Squibb, Dynavax, Gilead Sciences, Janssen, Lab for Advanced Medicine, Novartis, and Roche and fees for non-CME/CE services from Alnylam, Bristol-Myers Squibb, Dynavax, Gilead Sciences, and Roche.

Faculty

Steven L. Flamm, MD

Chief, Hepatology Program
Professor of Medicine
Medical Director
, Liver Transplantation
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Steven L. Flamm, MD, has disclosed that he has received consulting fees and funds for research support from Gilead Sciences.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Associate Scientific Director

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with chronic HBV infection.

Goal

The goal of this activity is to improve learners’ competence in applying evidence-based best practices in the management of patients with HBV infection.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 07, 2020, through July 06, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download free expert-authored slides reviewing HBV management recommendations for specific patient populations and learn how expert faculty approach complex cases

person default Joseph Ahn, MD, MS, MBA Anna Christina L. dela Cruz, MD Released: July 21, 2020

Watch this interactive presentation from CCO to learn how expert faculty weigh factors to determine the optimal management strategy for complex patients with HBV infection

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Program Director
person default Joseph Ahn, MD, MS, MBA Anna Christina L. dela Cruz, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 20, 2020 Expired: July 19, 2021

CCO commentary from Pietro Lampertico, MD, PhD, on the pros and cons of discontinuing NA therapy in patients with chronic HBV

person default Pietro Lampertico, MD, PhD Released: July 10, 2020

Download free expert-authored slides reviewing HBV treatment candidacy and individualizing treatment strategies and monitoring for specific patients

Steven L. Flamm, MD Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Released: July 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?